News
IMX-110 + anti-PD-1 Combination Produced Extended Median Survival in Genetic Pancreatic Cancer Mouse Model, Bolstering Planned 2022 IMX-110 Combination Clinical Trial Rationale Immix Biopharma ...
IMX-110 + Beigene/Novartis anti-PD-1 Tislelizumab combination designed to enhance response to solid tumors by turning immunologically “cold” tumors “hot”Initial data anticipated in 1H 2023 ...
The biopharma company said IMX-110 produced a 50 percent response rate after 1 cycle of treatment as a monotherapy in the first line-therapy-resistant cancer - soft tissue sarcoma mice study.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback